Business Wire

HD Medical at CES Unveils HealthyU™, the World’s First Intelligent All-in-one Remote Patient Monitor for Telehealth and Wellness

Share

At CES’21, HD Medical Inc. today introduces HealthyU™, an intelligent remote patient monitoring device, in response to the ongoing challenges of remote Telehealth, Cardiac Care, and Wellness during the pandemic and beyond.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210111005444/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

HealthyU™, the World’s First Intelligent All-in-one Remote Patient Monitor for Telehealth and Wellness. HD Medical Inc.'s HealthyU™ is an at-home monitoring device that addresses the ongoing challenges of remote Telehealth, Cardiac Care, and Wellness during the pandemic and beyond. (Graphic: Business Wire)

HealthyU™ is the first home device to provide:

  • 7-lead ECG (without wires)
  • Heart Sounds with Murmur Analysis
  • Lung Sounds
  • Heart Rate
  • Pulse Oximetry (SpO2 / blood oxygen saturation)
  • Temperature
  • Respiratory Rate
  • Cuffless Blood Pressure Trend

The Future of Telehealth, Home Monitoring, and Wellness

As the medical community seek new ways to deliver care, HealthyU™ takes multiple complex healthcare devices and turns them into one easy-to-use device for the patient and the provider to connect via a simple HD App and HD Cloud Platform for Intelligent Insights, or also with any video conferencing and screen sharing tool for Remote Consultation.

Providers can listen live to the heart and lung sounds using HD Steth™, HD Medical’s flagship intelligent stethoscope technology, cleared by FDA in July 2020 for Electronic Stethoscope, Phonocardiograph and Electrocardiograph.

Created with and available first to those with cardiac care and monitoring needs, HealthyU™ is available to clinical partners for research and corporate wellness partners seeking employee wellness offerings of this caliber, as well as for Telehealth pilot programs under IRB Protocol in accordance with FDA Regulations. HD Medical will be seeking Emergency Use Authorization from the FDA to make available in the U.S. and enable fully informed at-home doctor-patient visits during the pandemic and beyond.

HD Medical at CES Unveils HealthyU

“I’ve been treating patients remotely for nearly a year now and the pandemic has severely limited my ability to understand my patient’s condition. As we move forward, telehealth represents a paradigm shift in healthcare delivery during the pandemic and beyond. HealthyU will play a critical role and promises to not only save lives but also improve the quality of life for all patients,” said Dr. Nelson B. Schiller, MD, FACC, FRCP, Professor of Medicine & Anesthesia, UCSF.

"HealthyU is one of those rare medical devices that is truly a game changer in patient care. Being so user friendly and clinically sound, this device can be used in many different clinical scenarios and can truly be a lifesaver for multitudes of patients, who have the possibility of obtaining care while at home," said Dr. Shaun Setty, MD of The Larry and Helen Hoag Endowed Chair of Pediatric Cardiovascular Surgery in Los Angeles, CA.

“2020 has put greater emphasis on the need to advance remote patient monitoring technology, which is why we have prioritized bringing integrated sensors and intelligent insights into the home making it easy for patients to use and viable for providers to leverage during care,” said Arvind Thiagarajan, founder and CEO of HD Medical. “HealthyU™ performs wireless ECG outside of the hospital while incorporating auscultation and other important vitals. By simplifying the remote monitoring process, we’ve ensured this technology can be leveraged by anyone that needs it.”

HealthyU is currently intended for investigational use only, not for sale in the United States until after FDA clearance. HD Medical expects that HealthyU will be available for sale in the US by the third quarter of 2021, subject to FDA clearance process, which is being undertaken expeditiously. In the meantime, HealthyU will be available to clinical partners for research and corporate wellness programs, as well as telehealth pilot programs under the IRB protocol in accordance with FDA regulations.

To become a HealthyU™ partner, email info@hdmedicalgroup.com.

About HD Medical, Inc.

HD Medical, Inc. is a Silicon Valley-based innovator of digital health solutions for AI-enabled detection and management of cardiovascular disease (CVD). HD Steth has been awarded FDA clearance (K201299). The company delivers its intelligent cardiac care solutions and products globally to medical professionals and institutions through channel partners. Visit www.HealthyU.ai and www.hdmedicalgroup.com.

Note to editors: HealthyU, HD Steth, HD App, and HD Cloud Platform are registered trademarks of HD Medical, Inc. All other product, service or organization names remain the property of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Kristi Furrer
HD Medical, Inc.
kristi@hdmedicalgroup.com
408-908-8900

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LambdaTest and SVAM International Inc. Announce Partnership to Transform Quality Engineering for Businesses26.11.2025 19:00:00 EET | Press release

LambdaTest, a Gen-AI native quality engineering platform, announced a partnership with SVAM International, Inc., a global leader in digital transformation services. This strategic alliance marks a significant step forward in their mission to transform quality engineering for businesses worldwide. The partnership allows LambdaTest to extend its AI-native quality engineering capabilities into SVAM’s extensive digital transformation ecosystem. By integrating with SVAM’s experience in large-scale application development, testing, and delivery across major New York State and City agencies, as well as their platform expertise across Salesforce, ServiceNow, and Dynamics365, LambdaTest will empower more enterprises to modernize their software delivery pipelines. With LambdaTest’s intelligent test orchestration and execution engine at the core, teams can test smarter, accelerate release cycles, and achieve faster time-to-market at scale. Founded in 2017, LambdaTest is headquartered in San Franc

GLORY Acquires Remaining Equity Shares in Acrelec Group26.11.2025 17:11:00 EET | Press release

Glory Global Solutions (International) Ltd, a wholly-owned subsidiary of GLORY Ltd. [TYO:6457], has announced the acquisition of the remaining equity shares in Acrelec Group SAS. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251126039437/en/ Acrelec is a global technology company focused on reinventing the customer experience for restaurant and retail brands. Leveraging decades of software, hardware and service expertise, the company develops and integrates new platforms that increase customer engagement, optimize efficiency and improve operations. With over 120,000 installations across more than 70 countries, Acrelec counts many of the world’s best-known restaurant mega-brands among its customers. We announce that Jalel Souissi has left the Acrelec Group following the completion of the recent share acquisition. Jalel Souissi has played a pivotal role in the development and success of Acrelec, serving as Co-Founder and Co-C

Cegid Acquires Shine to Accelerate the Path of Becoming Europe's Leading Financial Copilot for SMBs and Accountants26.11.2025 15:00:00 EET | Press release

Cegid, a European leader in cloud software for finance, accounting, HR, and retail software, and Shine, a fast-growing European fintech unicorn providing digital business accounts and payments, e-invoicing, accounting, and payroll software to small businesses across Europe, announced today that the companies have entered a definitive agreement to join forces to form a European champion and become a leading provider of software for businesses and their accountants. This transformational combination will create the first fully integrated, cloud-native and AI-driven financial hub for SMBs and accounting professionals in Europe – bringing together market-leading capabilities in e-invoicing, accounting, digital business accounts and payments, tax, HR, and payroll in a single unified platform. Accelerating Cegid’s European growth strategy by serving more than one million SMBs, and 15,000 accountants Shine brings to Cegid more than 400,000 SMB customers, a strong brand, and a highly scalable

U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma26.11.2025 13:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to a New Drug Application (NDA) for sonrotoclax, a next-generation BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase (BTK) inhibitor. “Sonrotoclax is advancing with remarkable speed, from Breakthrough Therapy Designation to Priority Review, all within a short window,” said Lai Wang, Ph.D., Global Head of R&D at BeOne. “That pace reflects both the strength of the data and the urgency of the need for patients with R/R MCL. With rapid, deep, and durable responses and a manageable safety profile, sonrotoclax is emerging as a potential best-in-class BCL2 inhibitor, alongside our two other transformative hematology assets – BTK inhibitor BRUKINSA, and investigational BTK degrader BGB-16

Modon Holding Announces a Strategic Investment in Wellington Lifestyle Partners, Expanding Its Global Portfolio in Luxury Lifestyle Destination Development26.11.2025 12:15:00 EET | Press release

Abu Dhabi-based Modon Holding P.S.C (“Modon”) today announced a strategic investment in Wellington Lifestyle Partners (“WLP”), joining a consortium of existing investors in the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251125937208/en/ Aerial shot of Wellington International (Photo: AETOSWire) Modon’s investment will support the long-term development of Wellington International equestrian showgrounds and deliver a landmark ultra-luxury real estate development featuring high-end residences, a boutique hotel, a commercial marketplace and a championship golf course located in Wellington, Florida – a global icon of equestrian sport. This investment marks Modon’s first direct investment in an equestrian led development in the United States, complementing its existing global portfolio, and reinforcing its strategy to partner with leading international organisations in expanding its presence across ultra-luxury destin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye